Substance Use Disorder in Chemsex Practice

Not Applicable

Not yet recruiting

• Conditions: Addiction Chemical; Use, Substance

• Registration Number: NCT06476873
• Lead Sponsor: Centre Hospitalier Charles Perrens, Bordeaux

Brief Summary

The main aim of this descriptive cross-sectional study is to assess the prevalence of chemsex substance use disorder among chemsexers via an online self-questionnaire.

Detailed Description

Chemsex appeared in Europe around 2006 and in France in 2010. It involves the use of psychoactive substances in a sexual context to enhance, initiate, facilitate or prolong sexual intercourse through the psychoactive effects of the molecules consumed. These molecules are essentially synthetic cathinones, GHB/GBL, MDMA, methamphetamines, cocaine and ketamine. These products are often used in combination with erectile dysfunction treatments (side effects of the molecules). This practice is thought to affect almost 20% of MSM.

This use has numerous social, somatic, psychiatric and addictive consequences. Studies have mainly focused on infectious risks, psychiatric complications (e.g. anxiety and depression) or the prevalence of this phenomenon. However, no study has assessed the prevalence of chemsex-related substance use disorders among these users.

Study Timeline

• Status Verified: 2024-06
• Study First Submitted: 2024-06-17
• Study First Submitted QC: 2024-06-21
• Last Update Submitted: 2024-06-21
• Study First Posted: 2024-06-27
• Last Update Posted: 2024-06-27
• Study Start: 2024-07-01
• Primary Completion: 2025-04-30
• Study Completion: 2025-08-30

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 1000

Inclusion Criteria

• Be 18 years of age or older.
• Proficiency in written French
• Have practised chemsex at least once in the last 12 months.
• Agree to participate in the study.

Exclusion Criteria

• Have not experimented with chemsex in the last 12 months
• Participation in other ongoing research
• Insufficient written comprehension of French

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
DSM-5 diagnosis of substance use disorder for chemsex.	1 day	Assessment of the prevalence of chemsex substance use disorder among chemsexers via an online self-questionnaire.

Secondary Outcome Measures

Name	Time	Method
Describing the consumption practices of this population	1 day	Consumption practices
Describing the sociodemographic characteristics of this population	1 day	Socio-demographic characteristics
Describing the sexual practices of this population	1 day	Sexual practices
Explore the existence of chemsex use disorder as a clinical entity in its own right	1 day	DSM-5 diagnostic criteria for substance use disorder, adapted to assess chemsex addiction as a single clinical entity

Trial Locations

Locations (1)

Centre Hospitalier Charles PERRENS; 🇫🇷 Bordeaux, France